RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies-Reference-Cited by-同舟云学术

RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies

Published:2023-01-04 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Bigenwald Camille¹²³⁴,Haddad Yacine¹³,Thelemaque Cassandra¹³,Carrier Agathe¹³⁴,Birebent Roxanne¹³⁴,Ly Pierre¹³⁴,Flament Caroline¹³,Lahmar Imran¹³⁴,de Sousa Eric⁵,Maeurer Markus⁵⁶,Miyara Makoto⁷,Assi Tarek¹²,Castilla-Llorente Cristina¹²,Willekens Christophe²⁴,Fayemi Céline¹²,Lazarovici Julien¹²,Marabelle Aurélien¹³⁴⁸⁹,Derosa Lisa¹³⁴⁸,Ribrag Vincent¹²,Zitvogel Laurence¹³⁴⁸

Affiliation:

1. Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France

2. Hematology Department, Gustave Roussy Cancer Campus, Villejuif, France

3. Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France

4. Université Paris-Saclay, Gustave Roussy, Villejuif, France

5. ImmunoTherapy/ ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, Portugal

6. Medizinische Klinik, Johannes Gutenberg University, Mainz, Germany

7. Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France

8. Center of Clinical Investigations in Biotherapies of Cancer (BIOTHERIS), Villejuif, France

9. Département d’Innovation Thérapeutique (DITEP), Gustave Roussy Cancer Campus, Villejuif, France

Funder

author(s) reported that there is no funding associated with the work featured in this article

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2163785

Reference23 articles.

1. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)